Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lepodisiran sodium by Eli Lilly and Co for Atherosclerosis: Likelihood of Approval
Lepodisiran sodium is under clinical development by Eli Lilly and Co and currently in Phase III for Atherosclerosis. According to...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Lepodisiran sodium?
Lepodisiran sodium is an antisense rnai oligonucleotide commercialized by Eli Lilly and Co, with a leading Phase III program in...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Lepodisiran sodium?
Lepodisiran sodium is an antisense rnai oligonucleotide commercialized by Eli Lilly and Co, with a leading Phase III program in...